Medmonk

Medmonk, founded in 2012, is a biotechnology and pharmaceutical startup with a clear mission to revolutionize patient access to vital therapies. The company's dedication to transforming the way patients access medications for rare conditions is evident in their approach, which is grounded in two pivotal principles: 'Speed to Therapy' and providing 'Customization for Your Brand'. The startup acknowledges the need for agile, adaptive solutions for pharmaceutical manufacturers facing the unique challenges of rare diseases and niche brands. Medmonk expertly manages brand support for these rare conditions, ensuring coverage through pharmacy and medical benefits. What sets Medmonk apart is its in-depth expertise in rare disease brand management, robust network of specialty pharmacies, and seamless integration with 98% of specialty pharmacies, buy & bill facilities, and infusion centers nationwide. The last investment in Medmonk was a INR10.00M Seed Round investment on 10 October 2016 by Sudip Bandopadhyay, Rahul Singh, and Mohit Goel. In the complex terrain of today's healthcare, Medmonk plays a pivotal role in maintaining patient health trajectories, emphasizing sustained health and well-being by ensuring timely treatment. The company's platform streamlines the processes of patient enrollment in hub services, co-pay assistance, and reimbursement support, aligning with medical and pharmacy benefits. Medmonk's dedication to expediting treatment delivery aligns with its philosophy that timely access to medications is a trifecta of success for the patient, healthcare provider, and pharmaceutical brand.